Cargando…

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia

Treated AML patients often have measurable residual disease (MRD) due to persisting low-level clones. This study assessed whether residual post-treatment somatic mutations, detected by NGS, were significantly prognostic for subsequent clinical outcomes. AML patients (n = 128) underwent both pre-and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yonghong, Solis-Ruiz, Jose, Yang, Fei, Long, Nicola, Tong, Carmen H., Lacbawan, Felicitas L., Racke, Frederick K., Press, Richard D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123056/ https://www.ncbi.nlm.nih.gov/pubmed/37088803 http://dx.doi.org/10.1038/s41408-023-00833-7

Ejemplares similares

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

P1263: A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES
por: Hebert, L., et al.
Publicado: (2022)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

Vidjil add‐on for MRD quantification of samples processed using the EuroClonality‐NGS protocol
por: Giusti, Guilherme Navarro Nilo, et al.
Publicado: (2023)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Publicado: (2022)

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia
por: Shao, Jianming, et al.
Publicado: (2023)

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
por: Loo, Sun, et al.
Publicado: (2022)

How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring
por: Talami, Annalisa, et al.
Publicado: (2021)

P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.
por: Jimenez-Vicente, Carlos, et al.
Publicado: (2023)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2020)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia
por: Czyz, Anna, et al.
Publicado: (2019)

Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
por: Patkar, Nikhil, et al.
Publicado: (2021)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Rare e14a3 (b3a3) BCR-ABL Fusion in Chronic Myeloid Leukemia in India: The Threats and Challenges in Monitoring Minimal Residual Disease (MRD)
por: Vaniawala, Salil, et al.
Publicado: (2013)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
por: Feller, N, et al.
Publicado: (2013)

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT
por: O Marani, L., et al.
Publicado: (2022)

Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Sato, T, et al.
Publicado: (2014)

Infectious Events Prior to Chemotherapy Initiation in Children with Acute Myeloid Leukemia
por: Portwine, Carol, et al.
Publicado: (2013)

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis
por: Bhasin, Swati S., et al.
Publicado: (2023)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Hao, Qi, et al.
Publicado: (2021)

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms
por: Rosenthal, Sun Hee, et al.
Publicado: (2021)

P383: THE NEXT-GENERATION SEQUENCING (NGS) BASED MRD ASSESSMENT COULD BETTER PREDICT RELAPSE THAN MULTIPARAMETER FLOW CYTOMETRY (MFC) IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Yan, Nan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a6cbprig1j1l09g12bfiinsmfl